Tasos Konidaris - Mar 12, 2022 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President & CFO
Signature: /s/ Jason Daly, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 12, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/15/2022, 05:30 PM
Previous filing: Mar 3, 2022
Next filing: Mar 3, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+87.7K	+70.79%		212K	Mar 12, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-87.7K	-33.33%	$0.00	175K	Mar 12, 2022	Class A Common Stock	87.7K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.